Wire · opportunities
Late-Breaking Clinical Trial Results Announced at The VEINS 2026
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
The VEINS 2026 conference revealed late-breaking clinical trial results demonstrating the safety and effectiveness of new venous disease treatments, including cyanoacrylate closure for severe venous ulcers, a percutaneous ligation device with sclerotherapy, and a real-world registry for the Abre venous stent system.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 4 Oct 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
You face a clearer path to market with new venous treatment devices proving safety and efficacy in late-stage clinical trials. You can build or align product development strategies around these validated technologies to accelerate adoption and funding interest.
◆ Coverage
2 sources · first reported 4 Oct 2026 · latest 5 Oct 2026
◆ Related on Wire
◆ Topics